Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (September 2019)
23 slides from Biorestorative Therapies's investor presentation, Sep 6, 2019
Slide 1: BioRestorative Therapies
biorestorative therapies “BIOLOGIC PROBLEMS - BIOLOGIC SOLUTIONS”
Slide 2: Disclaimer and Cautionary Note on Forward Looking Statements
DISCLAIMER AND CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY") THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE
Slide 3: Executive Summary
EXECUTIVE SUMMARY Who is BRTX? + BioRestorative Therapies, Inc. ("BRTX") was founded by a team of scientists and researchers committed to developing stem cell therapies to address unmet medical needs + We believe that our advances in cell biology harbor great promise in conditioning our bodies’ own
Slide 4: Company Highlights
COMPANY HIGHLIGHT: @ Disruptive Platform Technology in Cellular Therapy Addressing Large Unmet Needs; Multi-Billion Dollar Market Opportunities @ Exploring Diverse Pipeline Opportunities within and outside of Spine and Obesity o> We Believe that Preliminary Data May Be Indicative of Positive Trial O
Slide 5: Corporate History & Accomplishments
2011 Established CORPORATE HISTORY & ACCOMPLISHMENTS 2012 Established Scientific Advisory Board - Selected Wayne Marasco, MD, PhD as Chairman 2012 Acquired the US and certain WW rights to IP for ThermoStem® Metabolic —_Disc/Spine Program for cLDD Program. 2010 Restructured & repurposed: existing pub
Slide 6: Cell-Based Therapies in Diversified Markets
CELL-BASED THERAPIES IN DIVERSIFIED MARKETS DISC/SPINE + Lead investigational therapeutic product BRTX-100 + Autologous (patient's own) cell-based biologic * Hypoxic (low oxygen) cultured, bone marrow-derived * Single intradiscal injection — anticipated 30 minute in-office procedure + Prior human da
Slide 7: Near-Term Goals
NEAR-TERM GOALS Announce contracts with Clinical Research Organization (CRO) & Contract Manufacturing Organization (CMO) Initiate pre-clinical animal study for metabolic program Issuance of new metabolic patents manufacturing clear Commencement of FDA Phase 2 clinical trial Anticipated data to be pu
Slide 8: Defined Health Report
DEFINED HEALTH REPORT In May 2018, Defined Health (a bio-consulting company) conducted a company sponsored blinded study with relevant key opinion leaders to provide an independent review of BRTX-100 DefinedHealth 2 CELLO HEALTH business Key Findings Include: + Stem-cell therapies have "great potent
Slide 9: Scientific Advisory Board
SCIENTIFIC ADVISORY BOAR Chairman of SAB WAYNE MARASCO, MD, PhD Wayne Marasco, M.D, Ph.D. is a principal faculty member of Harvard Stem Cell Institute as well as a Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medic
Slide 10: Impact on Public Health and Economy
ON AND ECONOMY IMPACT ON PUBLIC HEALTH & COST ASSOCIATED WITH NATIONAL OPIOID CRISIS bed National Life Expectancy (age 25-54) * 99% of global consumption of hydrocodone occurs in the United States (4.6% of the world's population) and 83% for oxycodone ' * The US leads the world in per capita consump
Slide 11: Large and Growing Market Opportunity
LARGE AND GROWING MARKET OPPORTUNITY am BETWEEN 1 1 250MILLION' 25 MILLION’ 12 MILLION 5.6 MILLION 500,000 American American adults with American adults with Americans have pain adult population chronic lower back diagnosed and treated disc caused by a protruding & 1 MILLION pain prevalence degenera
Slide 12: Conservative Treatments
CONSERVATIVE TREATMENTS OFTEN RECURRENT ORAL MEDICATION TREATMENT. $1,000 - $2,000 «4 Annually INJECTION TREATMENT 8,000 3 Annually $2.0 2 injections per treatment -semi-annual treatment PHYSICAL MEASURES $20,000 2 Annually $200 per sess Sions per week OF CARE: CLINICAL AND ECO IC PROBLEM SURGICAL T
Slide 13: Trial Design
TRI DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with cLDD Study Design and Patient Population Primary Endpoints: Primary Outcome Measure: Safety Efficacy Endpoint: The efficacy endpoint is clinical response, defined as at least a 30% decrease in pain as meas
Slide 14: BRTX-100 Production Process
BRTX-100 PRODUCTION PROCESS Collection and Shipment of Patient’s Bone Marrow and Blood to Cell Production Manufacturer Production of BRTX-100 Hypoxic Culturing of Stem Cells Thawing and Injection of BRTX-100 into Patient's Disc BRTX-100 PRODUCTION PROCESS Shipment of BRTX-100 Formulation and Cryopre
Slide 15: Positive Human Data
POSITIVE HUMAN DAT, HUMAN DATA FROM STUDIES OF THERAPIES SIMILAR TO BRTX-100 SHOW REDUCED PAIN, INCREASED FUNCTION, AND AN ABSENCE OF SIGNIFICANT SAFETY ISSUES WITH A DURABLE RESPONSE Journal of Translational Medicine Treatment of lumbar degenerative o— disc disease-associated radicular pain with cu
Slide 16: Competitive Landscape
COMPETITIVE LANDSCAPE PRODUCT & DESCRIPTION KEY ATTRIBUTES STAGE OF DEVELOPMENT biorestordtlve BRTX-100 adult stem cell biologic, administered via anticipated 30-minute in-office intradiscal injection Hypoxic cultured — in low oxygen environment (5%) Autologous — uses patients own stem cells Autolog
Slide 17: Metabolic Disease Indications
MIGRAINES, DEPRESSION, PSEUDOTUMOR CEREBRI, OBSTRUCTIVE SLECP APLIEA ‘CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, NON-ALCOHOUC FATTY LIVER DISEASE TYPE 2 OIABETES MELUTUS, METABOUC SYNDROME POLYCYSTIC OVARIAN SYNDROME VENOUS STASIS DISEASE 4 L— ¥ a 8 @ CARDIOVASCULAR DISEASE, HYPERTENSION DYSUMDE
Slide 18: Intellectual Property
INTELLECTUAL PROPERTY PROGRAM: PROGRAM: DISC/SPINE METABOLIC as —- (THERMOSTEM®) ort ae PATENTS PATENT TITLES PATENT TITLES + Brown Fat Compositions and Methods + Human Brown Adipose Derived Stem Cells and Uses + Non-naturally occurring three-dimensional (3D) Brown Adipose-Derived Stem Cell aggregat
Slide 19: Research & Development
RESEARCH & DEVELOPMENT Hypoxic BM-MSC IC LUMBAR DISC DISEASE BADSC THERMOSTEM® TYPE 2 DIABETES @ cossrvv ———-: STIC OVARIAN SYNDROME 19
Slide 20: Leadership
LEADERSHIP MARK WEINREB CEO & PRESIDENT ‘Mark Weinreb has served as CEO of the Company since October 2010 and has significant experience in running public companies. He previously served as the Chief Executive Officer and Chairman of the Board of Directors of Phase Ill Medical, Inc. where he orchest
Slide 21: Board of Directors
BOARD OF DIRECTORS A. JEFFREY RADOV Director Mr. Radov is an entrepreneur and businessman with 35 years of experience in media, communications and financial endeavors. He was a founding executive of About.Com, Inc, an online information source, and was its EVP of Business Development and Chief Finan
Slide 22: Company Highlights
COMPANY HIGHLIGHT: @ Disruptive Platform Technology in Cellular Therapy Addressing Large Unmet Needs; Multi-Billion Dollar Market Opportunities @ Exploring Diverse Pipeline Opportunities within and outside of Spine and Obesity o> We Believe that Preliminary Data May Be Indicative of Positive Trial O
Slide 23: BioRestorative Therapies Contact
biorestordt\lve therapies “BIOLOGIC PROBLEMS - BIOLOGIC SOLUTIONS” Mark Weinreb, ceo Lance Alstodt, eve & Chief Strategy Officer mweinreb@biorestorative.com lalstodt@biorestorative.com (631) 760-8401 (631) 760-8406 www.BRTX.com | 40 Marcus Drive, Suite One, Melville, NY 11747
BioRestorative Therapies — Investor Presentation (September 2019) on 6ix